Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2017

View Archived Issues

Shire reports key events of second quarter 2017

Daiichi Sankyo signs investment contract with Osaka University spin-off Cuorips

Novel LpxC inhibitor demonstrates efficacy in mouse model of bubonic plague

Kiromic conducts four phase I/II trials of its TAPA-pulsed dendritic cell vaccine

Extracellular phosphorylation of EphB2 regulates pathological pain

First-in-human results for prophylactic mRNA-based rabies vaccine

Induced pluripotent stem cells used to generate neurons for study of tau aggregation

Cyclacel selects recommended phase II dose for CYC-065

Zynerba Pharmaceuticals presents topline data from phase II STAR 1 trial of ZYN-002

Alligator Bioscience and Stanford University expand immuno-oncology collaboration

Phase III OPTIMA trial of ThermoDox in primary liver cancer recommended to continue

Positive topline data from first patient cohort of PIONEER-HCM phase II trial of mavacamten

FDA issues complete response letter for latanoprostene bunod NDA

FibroGen reports phase II topline data on pamrevlumab in IPF

FDA awards orphan drug designation to Mytesi for short bowel syndrome

Gemphire presents topline data from ROYAL-1 phase IIb study of gemcabene

Zelboraf granted priority review and breakthrough therapy designation for Erdheim-Chester disease

Piclidenoson completes cardiodynamic safety study

Rebiotix initiates phase III trial of RBX-2660 to prevent recurrent C. difficile infection

Janssen reports results of APPROACH study of Ad26.Mos.HIV HIV-1 vaccine regimens

AntriaBio acquires rights to ActiveSite's plasma kallikrein inhibitor program

FDA grants orphan drug designation to tesevatinib for EGFR-mutated NSCLC

Mylan receives PEPFAR tentative approval for TLD fixed-dose combination regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...